Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 7

Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

April 7, 2025

Julia Rotow, MD, Edgardo S. Santos Castillero, MD, FACP, FASCO

Panelists discuss how various strategies have been developed to enhance the tolerability of intravenous amivantamab, including premedication, step-up dosing, and infusion rate adjustments. Adoption into clinical practice varies, with many institutions integrating these approaches to mitigate infusion-related reactions and improve patient outcomes.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC

EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification

EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC

EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC

EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC

EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC

Now Viewing

EP. 7: Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

EP. 8: Future Treatment Options in EGFR-Mutant NSCLC

Video content above is prompted by the following:

Various strategies have been developed to increase the tolerability of intravenous amivantamab. Have these strategies been adopted into your practice, and do you have any clinical pearls to share with our audience?